Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OKN-007 + Temozolomide + Radiotherapy in Newly Diagnosed Glioblastoma
NCT03587038Phase 1Active, not recruiting
- Sponsor
- University of Oklahoma
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of OKN-007 in glioblastoma (GBM) (2 arms), sponsored by University of Oklahoma. Primary endpoint: Maximum Tolerated Dose and Dose Limiting Toxicities at 5 years. Started Sep 2018; status: active, not recruiting.
02
Drugs
OKN-007
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03587038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587038.